Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias

BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-ABL specific tyrosine kinase inhibitors (TKIs). However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Morotti, Alessandro, Carrà, Giovanna, Panuzzo, Cristina, Crivellaro, Sabrina, Taulli, Riccardo, Guerrasio, Angelo, Saglio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710905/
https://www.ncbi.nlm.nih.gov/pubmed/26843864
http://dx.doi.org/10.1155/2015/612567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710905/
https://www.ncbi.nlm.nih.gov/pubmed/26843864
http://dx.doi.org/10.1155/2015/612567

Ejemplares similares